乳腺癌的分子分类与靶向治疗(3)
[12]Bild AH,Yao G,Chang JT,et al.Oncogenic Pathway signatures in human cancers as a guide to targeted therapies.Nature,2006,439:353-357.
[13]Liu R,Wang X,Chen GY,et al.The prognostic role of a gene signature from tumorigenic breast-cancer cells.N Engl J Med,2007,356:217-226
[14]Ray A，Nkhata KJ，Cleary MP.Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status.Int J Oncol,2007,30(6):1499-1509.
, http://www.100md.com
[15]Brunelli M,Manfrin E,Martignoni G,et al.HER2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations:impact on selecting patients .for herceptin therapy.Am J Clin Pathol,2008,129(6):907-911.
[16]Nishimura R,Okumura Y,Arima N.Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer :time to progression and survival.Breast Cancer,2008,15(1):57-64.
[17]Gilmer TM ,Cable L,Alligood K,et al.Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.Cancer Res,2008,68(2):571-579.
, http://www.100md.com
[18]Geyer CE,Forster J,Lindquist D,et al.Lapatinib Plus capecitabine for HER2 Positive advanced breast cancer.N Engl J Med,2006,355(26):2733-2743.
[19]Piechocki MP,Yoo GH,Dibbley SK,et al.Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.Cancer Res,2007,67(14):6825-6843.
[20]Modi S,DAndrea G,Norton L,et al.A phase I study of cetuximab/Paclitaxel in patients with advanced-stage breast cancer.Clin Breast Cancer ,2006,7(3):270-277.
, http://www.100md.com
[21]Ramaswanmy B,Elias AD,Kelbick NT,et al.phase Ⅱ trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients,Clin Cancer Res,2006,12(10):3124-3129.
[22]Mulgrew K,Kinneer K,Yao XT,et al.Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody,Abegrin .Mol Cancer Ther,2006,5(12):3122-3129.
[23]Gingras D,Boivin D,Deckers C,et al.Neovastat-a novel antiangiogenic drug for cancer therapy.Anticancer Drugs,2003,14(2):91-96.
, http://www.100md.com
[24]Goldstein S,Decker D,Severson D,et al.Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy cancer,2007,110(8):1687-1696.
[26]Ihemelandu CU,Naab TJ,Mezghebe HM,et al.Treatment and Survival outcome for molecular breast cancer subtypes in black women Ann Surg,2008,247(3):196-199.
[27]吴谦.布托啡诺复合罗哌卡因用于乳腺癌术后硬膜外镇痛的效果及安全性.中国医学创新，2010，7(2):76-77.
[28]傅芳萌,王川,康德勇,等.对比Her-2及性激素受体在乳腺癌原发灶及配对复发转移灶之间的表达.中国医学创新，2010，7(7):8-10.
【收稿日期】2011-08-18, 百拇医药(张品南 陈艳梅)
[13]Liu R,Wang X,Chen GY,et al.The prognostic role of a gene signature from tumorigenic breast-cancer cells.N Engl J Med,2007,356:217-226
[14]Ray A，Nkhata KJ，Cleary MP.Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status.Int J Oncol,2007,30(6):1499-1509.
, http://www.100md.com
[15]Brunelli M,Manfrin E,Martignoni G,et al.HER2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations:impact on selecting patients .for herceptin therapy.Am J Clin Pathol,2008,129(6):907-911.
[16]Nishimura R,Okumura Y,Arima N.Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer :time to progression and survival.Breast Cancer,2008,15(1):57-64.
[17]Gilmer TM ,Cable L,Alligood K,et al.Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.Cancer Res,2008,68(2):571-579.
, http://www.100md.com
[18]Geyer CE,Forster J,Lindquist D,et al.Lapatinib Plus capecitabine for HER2 Positive advanced breast cancer.N Engl J Med,2006,355(26):2733-2743.
[19]Piechocki MP,Yoo GH,Dibbley SK,et al.Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.Cancer Res,2007,67(14):6825-6843.
[20]Modi S,DAndrea G,Norton L,et al.A phase I study of cetuximab/Paclitaxel in patients with advanced-stage breast cancer.Clin Breast Cancer ,2006,7(3):270-277.
, http://www.100md.com
[21]Ramaswanmy B,Elias AD,Kelbick NT,et al.phase Ⅱ trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients,Clin Cancer Res,2006,12(10):3124-3129.
[22]Mulgrew K,Kinneer K,Yao XT,et al.Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody,Abegrin .Mol Cancer Ther,2006,5(12):3122-3129.
[23]Gingras D,Boivin D,Deckers C,et al.Neovastat-a novel antiangiogenic drug for cancer therapy.Anticancer Drugs,2003,14(2):91-96.
, http://www.100md.com
[24]Goldstein S,Decker D,Severson D,et al.Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy cancer,2007,110(8):1687-1696.
[26]Ihemelandu CU,Naab TJ,Mezghebe HM,et al.Treatment and Survival outcome for molecular breast cancer subtypes in black women Ann Surg,2008,247(3):196-199.
[27]吴谦.布托啡诺复合罗哌卡因用于乳腺癌术后硬膜外镇痛的效果及安全性.中国医学创新，2010，7(2):76-77.
[28]傅芳萌,王川,康德勇,等.对比Her-2及性激素受体在乳腺癌原发灶及配对复发转移灶之间的表达.中国医学创新，2010，7(7):8-10.
【收稿日期】2011-08-18, 百拇医药(张品南 陈艳梅)